82 results about "Renal Tubule Epithelium" patented technology

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

A bioartificial renal tubule is provided that forms an artificial kidney together with a bioartificial glomerulus suitable for continuous hemofiltration. The bioartificial renal tubule includes an artificial membrane having an inner surface coated with renal tubular epithelial cells and a vessel containing the artificial membrane. The cells are prevented by the use of a MEK inhibitor from being stratified and therefore form a confluent monolayer on the artificial membrane. The renal tubular epithelial cells are characterized in that the contact inhibition thereof is maintained by the use of the MEK inhibitor. The MEK inhibitor is preferably U0126. The attachment of cells capable of reproducing the function of a kidney allows dialysis to be continuously performed for 24 hours with high efficiency and also allows the ability of a renal tubule to reabsorb useful substances to be achieved.

The invention belongs to the traditional medicine technical field, which relates to a traditional Chinese medicine composition for curing early and intermediate chronic renal failure. Under the guidance of a traditional Chinese medicine theory that 'interior accumulation is blood stasis' and 'chronic diseases transforming to collaterals is blood stasis', with the treatment principle of differentiation of symptoms and sighs, differentiation of channels, and based on the principle of strengthening body resistance and reducing turbidity, promoting blood circulation and removing blood stasis, the invention adopts traditional medicine such as lanceolata, epicedium, salvia miltiorrhizae, prepared rhubarb, perilla, peach kernel and the like, which are made into the compositions. Confirmed by clinical and animal experiments, the invention has the renal protecting functions of improving clinical symptoms of patients with early and intermediate chronic renal failure, reducing retention of metabolites of bodies, improving anemia, adjusting lipid and calcium-phosphorus metabolism, reducing the expression of fibrosis factors in nephridial tissues, preventing and treating glomerulosclerosis, lightening renal tubule damage and renal interstitial inflammatory cell infiltration and delaying renal fibrosis. The invention has the advantages of safety, efficiency and low cost, which is applied to the long-term medication for patients with early and intermediate chronic renal failure.

A method of assessing kidney function in a human subject to aid in the diagnosis of renal tubule diseases or conditions specific to a particular renal tubule region, comprises contacting a urine sample from said subject with a panel of capture molecules, each capture molecule being capable of binding to a specific biomarker from at least one of the four major regions of the renal tubule, in particular the proximal, distal, collecting duct and loop of Henle regions, the detection of one or more biomarkers in the urine sample being indicative of damage in a corresponding region of the renal tubule. The method facilitates inter alia the non-invasive detection of renal tubule damage and serves as a prognostic method to determine the level of tubule damage and monitor the effectiveness of therapeutic treatment.

A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.

The invention discloses reagent sets and gene signatures for predicting onset of renal tubule injury in a subject. The invention also provides a necessary set of 186 genes useful for generating signatures of varying size and performance capable of predicting onset of renal tubule injury. The invention also provides methods, apparatuses and reagents useful for predicting future renal tubule injury based on expression levels of genes in the signatures. In one particular embodiment the invention provides a method for predict whether a compound will induce renal tubule injury using gene expression data from sub-acute treatments.

The invention provides a renal tubule detection and segmentation method based on UNET, which is used for detecting and segmenting an area where renal tubule tissue is located in a collected pathological image, and comprises a training stage and an inference stage; the training stage is used for marking renal tubule data, and training a UNET model; and the inference stage is used for applying the trained UNET model to detection and segmentation of renal tubular tissues in a pathological image. According to the segmentation method, the area corresponding to the renal tubular tissue in the pathological strip image can be accurately recognized, the adjacent renal tubular tissue can be well separated, digital film reading is facilitated, and the automation and accuracy of digital film reading are improved.

A method for the early identification and prediction of abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.

The invention discloses a human normal renal tubule primary cell and in-vitro isolated culture and application thereof. The cell is named human normal renal tubule primary cell XHRN-01, and the preservation number of the cell is CCTCC NO:C201970. An isolated culture method of the primary cell comprises the steps that the clinical postoperative excised tissue near the kidney cancer is acquired in vitro, no cancer cell infection is identified through the pathology, the blood vessels and adipose tissue in the tissue are removed, a tissue sample is subjected to collagenase / trypsin digestion, filtration and low-speed centrifugation to obtain cell pellets, after a red blood cell lysis buffer lyses red blood cells, a COMR complete medium is used for resuspending the cells, and a cell line is constructed through continuous cell culture. The cell can be applied in the physiological study on human normal cells, study on drug toxicity of in-vitro normal cells, study on the pathogenesis of the kidney cancer and related diseases including the renal cancer, chronic nephritis and infectious diseases and study on screening of therapeutic drugs.

The invention discloses a three-dimensional perfusion type cell culture device and an application thereof. The three-dimensional perfusion type cell culture device comprises a box body, a cover body and an elastic clamp, wherein a first circular groove is formed in the top surface of the box body, and a second circular groove with the same radius as the first circular groove is formed in the bottom surface of the cover body. In the cell culture device disclosed by the invention, vessels consisting of polyester fibers are arranged on the bottom surface of the groove, and a cell or tissue explant is positioned between two layers of vessels to form 'sandwich' culture; the vessels consisting of polyester fibers are used for replacing a scaffold material, so that the dead angle volume in cell culture is minimized to better conform to the in-vivo physiological microenvironment. A culture solution inlet channel and a culture solution outlet channel are formed on the side wall of the box body of the culture device respectively, and a culture solution flows into the groove cavity through the solution inlet channel and flows out through the solution outlet channel so as to realize perfusion culture. By adopting the device disclosed by the invention, the embryonic stem cell / progenitor cell at the new renal cortex part is successfully differentiated into renal tubule tissues.

The invention discloses a unilateral ureteral ligation recanalisation animal model and a building method thereof. The method comprises the following steps of: 1) preparing an elastic plastic tube; and 2) after implanting an elastic plastic fat pad into the left ureter of an SD male mouse to pressurize to perform ligation obstruction, performing a surgery 7 days later for the second time, in the surgery, taking out the elastic plastic tube, dredging the left ureter to release the left kidney obstruction and separate the envelope of the left kidney at the same time, and ligaturing the right ureter with a NO. 4 thread. In addition, the invention also discloses the animal model built by the method. The animal model can reduce renal functions and cause renal tubule mesenchyme fibrosis change. The model building period is short; the response is quick; the cost is low; the model is convenient to use; the performance of the model is stable; the repeatability is good; pathomorphological changes of kidney after obstruction can be observed; the functional level of the kidney can be studied; and the relation between the pathomorphological changes and the functional level can be embodied; and the animal model provides a new study target for clinical research and development of medicaments for preventing and treating renal fibrosis.

The invention belongs to the traditional medicine technical field, which relates to a traditional Chinese medicine composition for curing early and intermediate chronic renal failure. Under the guidance of a traditional Chinese medicine theory that 'interior accumulation is blood stasis' and 'chronic diseases transforming to collaterals is blood stasis', with the treatment principle of differentiation of symptoms and sighs, differentiation of channels, and based on the principle of strengthening body resistance and reducing turbidity, promoting blood circulation and removing blood stasis, the invention adopts traditional medicine such as lanceolata, epicedium, salvia miltiorrhizae, prepared rhubarb, perilla, peach kernel and the like, which are made into the compositions. Confirmed by clinical and animal experiments, the invention has the renal protecting functions of improving clinical symptoms of patients with early and intermediate chronic renal failure, reducing retention of metabolites of bodies, improving anemia, adjusting lipid and calcium-phosphorus metabolism, reducing the expression of fibrosis factors in nephridial tissues, preventing and treating glomerulosclerosis, lightening renal tubule damage and renal interstitial inflammatory cell infiltration and delaying renal fibrosis. The invention has the advantages of safety, efficiency and low cost, which is applied tothe long-term medication for patients with early and intermediate chronic renal failure.